Orphan Drug

Orphan Drug designates a pharmaceutical product developed specifically for treating rare diseases affecting small patient populations, typically defined as conditions impacting fewer than 200,000 individuals in the United States or diseases with prevalence below 5 per 10,000 in Europe, with regulatory frameworks providing incentives encouraging development despite limited commercial markets. Orphan drug designation programmes offer accelerated regulatory review, tax credits, regulatory fee waivers, and market exclusivity periods.

The biopharmaceutical industry has dramatically increased orphan drug development following incentive programme implementation, with numerous approvals transforming previously untreatable rare diseases into manageable conditions. Rare disease characteristics influencing development include small patient populations complicating clinical trial recruitment, disease heterogeneity, limited natural history understanding, and diagnostic challenges. Regulatory pathways accommodate rare disease challenges through flexible trial designs including smaller patient numbers, use of historical controls, and surrogate endpoints. Drug development strategies include repurposing existing drugs, developing platform approaches across related conditions, and employing innovative modalities including gene therapy. Patient advocacy organisations play crucial roles through funding research, facilitating trial recruitment, and providing natural history data. As therapeutic modalities advance, orphan drug development expands providing hope for patients with devastating rare diseases.